-
Under a new pact Gilead will combine its new boosting agent cobicistat with J&J's Prezista, a protease inhibitor. The companies also outlined ongoing talks on a separate pact on the
development and commercialization of a future single-tablet regimen
combining Prezista with Gilead's Emtriva, its experimental GS 7340 and
cobicistat. Gilead would be responsible for the development and
commercialization of the new STR on a worldwide basis.
28 June 2011 | FierceBiotech
-
AS part of efforts to expand treatment for People Living With HIV/AIDS (PLWHAs) and beat drug-resistance, an Indian company, Emcure Pharmaceuticals, has donated second line Anti Retroviral (ARV) drugs to the National Agency for the Control of AIDS
19 May 2011 | Moreover.com HIV/AIDS feed
-
The largest clinical trial to investigate treatment options for individuals whose first combination of anti-HIV medicines is no longer working has been announced following the recruitment of 1,200 HIV-positive individuals from across five African
18 May 2011 | University College Dublin
-
People with heavily drug-resistant HIV benefit from adding two nucleoside reverse transcriptase inhibitors (NRTIs) to a regimen that contains Isentress (raltegravir), even if their virus is partially or fully resistant to the NRTIs. These data were published online January 28 in the Journal of Acquired Immune Deficiency Syndromes.
02 February 2011 | AIDSMeds
-
Despite the Supreme Court’s directive last month to make second- line HIV/AIDS treatment available free of cost to all those who need it, patients in non-metros will have to wait till March.
12 January 2011 | DNA
-
The recent Supreme Court (SC) directive to allow patients
taking second- line drugs against HIV/AIDS to shift from private
hospitals to government-run ones has brought out a startling fact. It
has now come to light that many HIV patients were put on the very
expensive second-line drugs by unscrupulous private doctors even without
putting them in the first-line.
09 January 2011 | Mumbai Mirror
-
India has rejected an HIV drug patent application filed by US-based Abbott Laboratories, as it lacked novelty under domestic laws. The denial of patent will help domestic drug-makers to produce and market low-cost versions of this drug in the developing
03 January 2011 | Business-Standard
-
NEW DELHI: The Centre on Friday tried everything -- from huge costs to irrational treatment by private hospitals -- to express reservations about extending second-line treatment to all HIV positive patients, but the Supreme Court used the right to life argument to counter them. The government had said it was willing to extend second-line treatment costing Rs 28,500 each to all patients except ...
11 December 2010 | Times of India
-
LUSAKA, 23 November 2010 (PLUSNEWS) - Before Zambia's public health sector started providing free antiretroviral drugs (ARVs) to people living with HIV, Ephraim Banda bought his own medication. But his supply was often interrupted and the available drugs changed frequently and he is now one of a growing number of HIV-positive Zambians who have developed resistance to both first- and second-line ARV drug regimens.
23 November 2010 | IRIN Plus News
-
All HIV patients put on antiretroviral therapy before 2004 but who became resistant to those drugs will now receive the life saving
second line treatment free of cost from the National AIDS Control Organisation
(NACO).
13 November 2010 | Times of India
Talking points: a checklist for you and your doctorTalking points is designed to help you talk to your doctor about HIV
treatment.
Preventing HIVAn essential resource providing evidence-based information on preventing HIV infection. 
HIV treatment update – Winter 201206 February 2012The new edition of HIV treatment update (HTU) is now...
A visit from Wandsworth Oasis26 January 2012On Wednesday this
week, we were delighted to have a visit...
Adventurers with HIV – a photo gallery19 January 2012Back in
November we sent out a
call for adventurous people with...